Alopecia areata

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 5, Issue 2, 2011, Pages 98-107

  Hon, Kam Lun E ^a   Leung, Alexander K C ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Alopecia areata; Corticosteroids; Interleukin 31; Psychological stress

Indexed keywords

BETAMETHASONE DIPROPIONATE; CALCINEURIN INHIBITOR; CLOBETASOL PROPIONATE; CONTINUS COGGYGRIA EXTRACT; CORTICOSTEROID; CYCLOSPORIN; DERMATOLOGICAL AGENT; DIPHENCYPRONE; DITHRANOL; FLUOCINOLONE ACETONIDE; INTERLEUKIN 31; METHOXSALEN; METHYLPREDNISOLONE; MINOXIDIL; PIMECROLIMUS; PLANT EXTRACT; PREDNISOLONE; PREDNISONE; PSORALEN; SQUARIC ACID DIBUTYL ESTER; TACROLIMUS; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ACNE; ALOPECIA; ALOPECIA AREATA; APPLICATION SITE BURNING; ARTHRALGIA; ATROPHY; BLISTER; BURNING MOUTH SYNDROME; CASE FINDING; CONTACT DERMATITIS; CONTINUS COGGYGRIA; CYTOTOXIC T LYMPHOCYTE; DERMATITIS; DESQUAMATION; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; EPILUMINESCENCE MICROSCOPY; EXCIMER LASER; EYELID EDEMA; FACE EDEMA; FEVER; FOLLICULITIS; HAIR GROWTH; HAIR LOSS; HUMAN; HYPERTENSION; HYPERTRICHOSIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; INSOMNIA; LEUKODERMA; LOW LEVEL LASER THERAPY; LYMPHADENOPATHY; MEDICINAL PLANT; MENTAL DISEASE; MENTAL INSTABILITY; MOOD CHANGE; NONHUMAN; OSTEOPOROSIS; PHOTOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; PURPURA; REVIEW; SCAR FORMATION; SIDE EFFECT; SKIN ATROPHY; SKIN DEFECT; SKIN EDEMA; SKIN IRRITATION; STRIA; SYPHILIS; SYSTEMIC DISEASE; SYSTEMIC THERAPY; T LYMPHOCYTE ACTIVATION; TELANGIECTASIA; TINEA CAPITIS; TREATMENT DURATION; TRICHOTILLOMANIA; ULTRAVIOLET A RADIATION; URTICARIA; VITILIGO; WEIGHT GAIN; XEROSIS;

ADRENAL CORTEX HORMONES; ALOPECIA AREATA; ANIMALS; ANTIBODIES; HUMANS; IMMUNOTHERAPY; INTERLEUKINS; LASERS, EXCIMER; MINOXIDIL; REMISSION, SPONTANEOUS; RISK FACTORS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 79954500854     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221311795399291     Document Type: Review

References (126)

1. Leung AK., Alopecia areata. In: Leung AK, ed. Common Problems in Ambulatory Pediatrics. New York: Nova Science Publishers, Inc (in press).
2. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database of Systematic Reviews 2008; (2): CD004413.
3. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ, III. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995; 70(7): 628-33.
4. Gilhar A, Kalish RS. Alopecia areata: A tissue specific autoimmune disease of the hair follicle. Autoimmun Rev 2006; 5(1): 64-9.
5. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 2010; 62(2): 177-88.
6. Mukherjee N, Burkhart CN, Morrell DS. Treatment of alopecia areata in children. Pediatr Ann 2009; 38(7): 388-95.
7. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol 1992; 128(5): 702.
8. Hon KL, Leung TF, Wong Y, Ma KC, Fok TF. Skin diseases in chinese children at a pediatric dermatology center. Pediatr Dermatol 2004; 21(2): 109-12.
9. Muller SA, Winkelmann RK. Alopecia areata. An Evaluation of 736 patients. Arch Dermatol 1963; 88: 290-7.
10. Shellow WV, Edwards JE, Koo JY. Profile of alopecia areata: A questionnaire analysis of patient and family. Int J Dermatol 1992; 31(3): 186-9.
11. Hawit F, Silverberg NB. Alopecia areata in children. Cutis 2008; 82(2): 104-10.
12. Nanda A, Al Hasawi F, Alsaleh QA. A prospective survey of pediatric dermatology clinic patients in Kuwait: An analysis of 10,000 cases. Pediatr Dermatol 1999; 16(1): 6-11.
13. Seyrafi H, Akhiani M, Abbasi H, Mirpour S, Gholamrezanezhad A. Evaluation of the profile of alopecia areata and the prevalence of thyroid function test abnormalities and serum autoantibodies in Iranian patients. BMC Dermatol 2005; 5: 11.
14. Garg S, Messenger AG. Alopecia areata: Evidence-based treatments. Seminars in Cutaneous Medicine & Surgery 2009; 28(1): 15-18.
15. Price VH. Alopecia areata: Clinical aspects. Int J Dermatol 1991; 96(5): 68S.
16. Werth VP, White WL, Sanchez MR, Franks AG. Incidence of alopecia areata in lupus erythematosus. Arch Dermatol1992; 128(3): 368-71.
17. Leung AK, Robson WL. Hair loss in children. J R Soc Health 1993; 113(5): 252-6.
18. Tan E, Tay YK, Goh CL, Chin GY. The pattern and profile of alopecia areata in Singapore--a study of 219 Asians. Int J Dermatol 2002; 41(11): 748-53.
19. Kakourou T, Karachristou K, Chrousos G. A case series of alopecia areata in children: Impact of personal and family history of stress and autoimmunity. J Eur Acad Dermatol Venereol 2007; 21(3): 356-9.
20. Hon KL, Leung AK, Ng PC. Unusual loss of body hair in childhood: Trichotillomania or alopecia. Adv Ther 2008; 25(4): 380-7.
21. Colombe BW, Price VH, Khoury EL, Garovoy MR, Lou CD. HLA class II antigen associations help to define two types of alopecia areata. J Am Acad Dermatol 1995; 33(5 Pt 1): 757-64.
22. Colombe BW, Lou CD, Price VH. The genetic basis of alopecia areata: HLA associations with patchy alopecia areata versus alopecia totalis and alopecia universalis Symposium Proceedings. J Invest Dermatol 1999; 4(3): 216-9.
23. Welsh EA, Clark HH, Epstein SZ. Human leukocyte antigen- DQB1*03 alleles are associated with alopecia areata. J Invest Dermatol 1994; 103: 758-63.
24. Price VH, Colombe BW. Heritable factors distinguish two types of alopecia areata. Dermatol Clin 1996; 14(4): 679-89.
25. Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med 1993; 66(6): 541-54.
26. Randall VA. Is alopecia areata an autoimmune disease?. Lancet 2001; 358(9297): 1922-4.
27. McElwee KJ, Tobin DJ, Bystryn JC, King LE, Jr., Sundberg JP. Alopecia areata: An autoimmune disease?. Exp Dermatol 1999; 8(5): 371-9.
28. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol 2000; 42(4): 549-66.
29. Perini GI, Veller FC, Cipriani R, Bettin A, Zecchino F, Peserico A. Life events and alopecia areata. Psychother Psychosom 1984; 41(1): 48-52.
30. Morales-Sánchez MA, Domínguez-Gómez MA, Jurado-Santa Cruz F, Peralta-Pedrero ML. Immunization and bacterial pathogens in the oropharynx as risk factors for alopecia areata. Actas Dermosifiliogr 2010; 101(5): 437-43.
31. van der Steen P, Traupe H, Happle R, Boezeman J, Strater R, Hamm H. The genetic risk for alopecia areata in first degree relatives of severely affected patients. An estimate. Acta Dermato- Venereologica 1992; 72(5): 373-5.
32. Martinez-Mir A, Zlotogorski A, Gordon D, Petukhova L, Mo J, Gilliam TC, et al. Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 2007; 80(2): 316-28.
33. Scerri L, Pace JL. Identical twins with identical alopecia areata. J Am Acad Dermatol 1992; 27(5 Pt 1): 766-7.
34. Carter PS, Banwell PE. Necrotising fasciitis: A new management algorithm based on clinical classification. Int Wound J 2004; 1(3): 189-98.
35. Du VA, Munro DD. Alopecia areata, autoimmunity, and Down's syndrome. Br Med J 1975; 1(5951): 191-2.
36. Friedmann PS. Alopecia areata and auto-immunity. Br J Dermatol 1981; 105(2): 153-7.
37. Paus R, Ito N, Takigawa M, Ito T. The Hair Follicle and Immune Privilege. J Investigative Dermatol Symposium Proceedings 2003; 8, 188-94.
38. Ito T, Ito N, Bettermann A, Tokura Y, Takigawa M, Paus R. Collapse and restoration of MHC class-I-dependent immune privilege: Exploiting the human hair follicle as a model. Am J Pathol 2004; 164(2): 623-34.
39. Paus R, Nickoloff BJ, Ito T. A 'hairy' privilege. Trends Immunol 2005; 26(1): 32-40.
40. Grandolfo M, Biscazzi AM, Pipoli M. Alopecia areata and autoimmunity. G Ital Dermatol Venereol 2008; 143(5): 277-81.
41. Hordinsky M, Ericson M. Autoimmunity: Alopecia areata. J Invest Dermatol 2004; 9(1): 73-8.
42. Lutz G, Bauer R. [Autoimmunity in alopecia areata. An assessment in 100 patients]. [German]. Hautarzt 1988; 39(1): 5-11.
43. Cunliffe WJ, Hall R, Stevenson CJ, Weightman D. Alopecia areata, thyroid disease and autoimmunity. Br J Dermatol 1969; 81(12): 877-81.
44. Lu W, Shapiro J, Yu M, Barekatain A, Lo B, Finner A, et al. Alopecia areata: Pathogenesis and potential for therapy. Expert Rev Mol Med 2006; 8(14): 1-19.
45. Kalish RS, Gilhar A. Alopecia areata: Autoimmunity-the evidence is compelling. J Invest Dermatol 2003; Symposium Proceedings. 8(2): 164-7.
46. Tang L, Cao L, Pelech S, Lui H, Shapiro J. Cytokines and signal transduction pathways mediated by anthralin in alopecia areataaffected Dundee experimental balding rats. J Invest Dermatol y 2003; Symposium Proceedings. 8(1): 87-90.
47. Mitchell AJ, Krull EA. Alopecia areata: Pathogenesis and treatment. J Am Acad Dermatol 1984; 11(5 Pt 1): 763-75.
48. Cetin ED, Savk E, Uslu M, Eskin M, Karul A. Investigation of the inflammatory mechanisms in alopecia areata. Am J Dermatopathol 2009; 31(1): 53-60.
49. Hordinsky MK, Kennedy W, Wendelschafer-Crabb G, Lewis S. Structure and function of cutaneous nerves in alopecia areata. J Invest Dermatol 1995; 104(5 Suppl): 28S-9.
50. Paus R, Arck P. Neuroendocrine perspectives in alopecia areata: Does stress play a role? J Invest Dermatol 2009; 129(6): 1324-6.
51. Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010; 466(7302): 113-7.
52. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: A long term follow-up study of 191 patients. J Am Acad Dermatol 2006; 55(3): 438-41.
53. Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol 1996; 35(1): 22-7.
54. Shapiro J, Madani S. Alopecia areata: Diagnosis and management. Int J Dermatol 1999; 38 (Suppl 1): 19-24.
55. Tosti A, De Padova MP, Caponeri GM, Liverani L, Gargano N, Veronesi S. Nail changes and alopecia areata. Giornale Italiano di Dermatologia e Venereologia 1985; 120(3): 169-71.
56. Sharma VK, Dawn G, Muralidhar S, Kumar B. Nail changes in 1000 Indian patients with alopecia areata. J Eur Acad Dermatol Venereol 1998; 10(2): 189-91.
57. Kasumagic-Halilovic E, Prohic A. Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol 2009; 23(2): 240-1.
58. Manolache L, Benea V. Stress in patients with alopecia areata and vitiligo. J Eur Acad Dermatol Venereol 2007; 21(7): 921-8.
59. Puavilai S, Puavilai G, Charuwichitratana S, Sakuntabhai A, Sriprachya-Anunt S. Prevalence of thyroid diseases in patients with alopecia areata. Int J Dermatol 1994; 33(9): 632-3.
60. Colon EA, Popkin MK, Callies AL, Dessert NJ, Hordinsky MK. Lifetime prevalence of psychiatric disorders in patients with alopecia areata. Compr Psychiatry 1991; 32(3): 245-51.
61. Liakopoulou M, Alifieraki T, Katideniou A, Kakourou T, Tselalidou E, Tsiantis J, et al. Children with alopecia areata: Psychiatric symptomatology and life events. J Am Acad Child Adolesc Psychiatry 1997; 36(5): 678-84.
62. van der SP, Boezeman J, Duller P, Happle R. Can alopecia areata be triggered by emotional stress? An uncontrolled evaluation of 178 patients with extensive hair loss. Acta Derm Venereol 1992; 72(4): 279-80.
63. Corazza GR, Andreani ML, Venturo N, Bernardi M, Tosti A, Gasbarrini G. Celiac disease and alopecia areata: Report of a new association.Gastroenterology 1995; 109(4): 1333-7.
64. Zampetti M, Filippetti R. Alopecia areata and celiac disease. Giornale Italiano di Dermatologia e Venereologia 2008; 143(2): 168.
65. Fessatou S, Kostaki M, Karpathios T. Coeliac disease and alopecia areata in childhood. J Paediatr Child Health 2003; 39(2): 152-4.
66. Han A, Mirmirani P. Clinical approach to the patient with alopecia. Semin Cutan Med Surg 2006; 25: 11-23.
67. Inui S, Nakajima T, Nakagawa K, Itami S. Clinical significance of dermoscopy in alopecia areata: Analysis of 300 cases. Int J Dermatol 2008; 47(7): 688-93.
68. Tokura Y, Sugita K, Kabashima K, Ito T, Yagi H. Alopecia universalis associated with impaired interleukin-4 production and low serum IgE level. J Am Acad Dermatol 2007; 57(2 Suppl): S22-5.
69. Goos M. The histopathology of alopecia areata. With special reference to the duration, location and progession of hair loss. [German]. Arch Dermatol Forsch 1971; 240(2): 160-72.
70. Whiting DA. Histopathology of alopecia areata in horizontal sections of scalp biopsies. J Invest Dermatol 1995; 104(5 Suppl): 26S-7S.
71. Madani S, Shapiro J. The scalp biopsy: Making it more efficient. Dermatol Surg 1999; 25(7): 537-8.
72. Christenson GA, Crow SJ. The characterization and treatment of trichotillomania. J Clin Psychiatry 1996; 57 (Suppl 8): 42-7.
73. Radmanesh M, Shafiei S, Naderi AH. Isolated eyebrow and eyelash trichotillomania mimicking alopecia areata. Int JDermatol 2006; 45(5): 557-60.
74. Bruce TO, Barwick LW, Wright HH. Diagnosis and management of trichotillomania in children and adolescents. Paediatric Drugs 2005; 7(6): 365-76.
75. Shelleh HH, Khan SA, Al Hatiti HS. Trichotillomania or alopecia areata? IntJ Dermatol2006; 45(10): 1196-8.
76. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: Part II. Treatment. J Am Acad Dermatol 2010; 62(2): 191-202.
77. Umbert, M. Dermatological pharmaceutical composition for the treatment of skin inflammation diseases, such as dermatitis, atopic dermatitis, vitiligo, alopecia areata, acne, psoriasis, pruritus or combinations of same.WO2009153373 (2009).
78. Bruning, E., Stone, V. I., Zhao, R. Compositions and methods of inducing hair growth utilizing Continus coggygria US7704533 (2010).
79. Gill KA Jr., Baxter DL. Alopecia totalis. Treatment with fluocinolone acetonide. Arch Dermatol 1963; 87: 384-6.
80. Pascher F, Kurtin S, Andrade R. Assay of 0.2 percent fluocinolone acetonide cream for alopecia areata and totalis. Efficacy and side effects including histologic study of the ensuing localized acneform response. Dermatologica 1970; 141(3): 193-202.
81. Montes LF. Topical halcinonide in alopecia areata and in alopecia totalis. J Cutaneous Pathol 1977; 4: 47.
82. Tosti A, De Padova MP, Minghetti G, Veronesi S. Therapies versus placebo in the treatment of patchy alopecia areata. J Am Acad Dermatol 1986; 15(2 Pt 1): 209-10.
83. Price VH, Willey A, Chen BK. Topical tacrolimus in alopecia areata. J Am Acad Dermatol 2005; 52(1): 138-9.
84. Boludc C, Hui H, Shapiro J. Alopecia areata. Emedicine. Available at: http://emedicine.medscape.com/article/1069931-overview [Accessed on: January 16, 2011].
85. Hon KL, Kam WY, Leung TF, Lam MC, Wong KY, Lee KC, et al. Steroid fears in children with eczema. Acta Paediatr 2006; 95(11): 1451-5.
86. Fiedler VC, Wendrow A, Szpunar GJ, Metzler C, DeVillez RL. Treatment-resistant alopecia areata. Response to combination therapy with minoxidil plus anthralin. Arch Dermatol 1990; 126(6): 756-9.
87. Fiedler VC. Alopecia areata: Current therapy. J Invest Dermatol 1991; 96(5): 69S-70S.
88. Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992; 128(11): 1467-73.
89. Arca E, Acikgoz G, Tastan HB, Kose O, Kurumlu Z. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology 2004; 209(2): 117-25.
90. Georgala S Befon A, Maniatopoulou E, Georgala C. Topical use of minoxidil in children and systemic side effects. Dermatology 2007; 214: 101-2.
91. Hoffmann R, Happle R. Topical immunotherapy in alopecia areata. What, how, and why? Dermatol Clin 1996; 14(4): 739-44.
92. Rokhsar CK, Shupack JL, Vafai JJ, Washenik K. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol 1998; 39(5 Pt 1): 751-61.
93. Happle R. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res 1980; 267(1): 109-14.
94. Hull SM, Pepall L, Cunliffe WJ. Alopecia areata in children: response to treatment with diphencyprone. Br J Dermatol 1991; 125(2): 164-8.
95. Schuttelaar ML, Hamstra JJ, Plinck EP, Peereboom-Wynia JD, Vuzevski VD, Mulder PG, et al. Alopecia areata in children: Treatment with diphencyprone. Br J Dermatol 1996; 135(4): 581-5.
96. Tosti A, Guidetti MS, Bardazzi F, Misciali C. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol 1996; 35: 199-201.
97. Mitchell AJ, Douglass MC. Topical photochemotherapy for alopecia areata. J Am Acad Dermatol 1985; 12(4): 644-9.
98. Taylor CR, Hawk JL. PUVA treatment of alopecia areata partialis, totalis and universalis: Audit of 10 years' experience at St John's Institute of Dermatology. Br J Dermatol 1995; 133(6): 914-8.
99. Sharma VK. Pulsed administration of corticosteroids in the treatment of alopecia areata. Int J Dermatol 1996; 35(2): 133-6.
100. Sharma VK, Muralidhar S. Treatment of widespread alopecia areata in young patients with monthly oral corticosteroid pulse. Pediatr Dermatol 1998; 15(4): 313-7.
101. Friedli A, Labarthe MP, Engelhardt E, Feldmann R, Salomon D, Saurat JH. Pulse methylprednisolone therapy for severe alopecia areata: An open prospective study of 45 patients. J Am Acad Dermatol 1998; 39(4 Pt 1): 597-602.
102. Seiter S, Ugurel S, Tilgen W, Reinhold U. High-dose pulse corticosteroid therapy in the treatment of severe alopecia areata. Dermatology 2001; 202(3): 230-4.
103. Assouly P, Reygagne P, Jouanique C, Matard B, Marechal E, Reynert P, et al. Intravenous pulse methylprednisolone therapy for severe alopecia areata: An open study of 66 patient. [French]. Ann Dermatol Venereol 2003; 130(3): 326-30.
104. Shaheedi-Dadras M, Karami A, Mollaei M, Moravej T, Malekzad F. Cyclosporine in the treatment of alopecia totalis and universalis. Arc Iran Med 2008; 11 (1): 90-3.
105. Fisher DA. Systemic steroids for treatment of alopecia areata. Arch Dermatol 1977; 113(12): 1731-12.
106. Shapiro J, Lui H, Tron V, Ho V. Systemic cyclosporine and lowdose prednisone in the treatment of chronic severe alopecia areata: A clinical and immunopathologic evaluation. J Am Acad Dermatol 1997; 36(1): 114-7.
107. Andreoli E, Mozzetta A, Provini A, Cacciaguerra MG, Paradisi M, Foglio BPG. Types of stress within child alopecia. Dermatol Psychosom 2002; 3: 26-9.
108. Peled JU. Psychosocial counseling may be best treatment for hair loss. Am Fam Physician 2004; 69(6): 1362.
109. Yano S, Nakamura K, Okochi H, Tamaki K. Analysis of the expression of cutaneous lymphocyte-associated antigen on the peripheral blood and cutaneous lymphocytes of alopecia areata patients. Acta Derm Venereol 2002; 82(2): 82-5.
110. Dillon SR. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 2004; 5: 752-60
111. Bondensgaard, K., Beckmann, R. Humanized antibody molecules specific for IL-31. US20090208494 (2009) & EP2215120 (2010).
112. Siadek, A. W., Bilsborough, J., Rene, S. Methods of using IL-31 monoclonal antibodies to reduce inflammation. US20090220417 (2009).
113. Siadak, A. W., Bilsborough, J. M., Rene, S. A. Variable region sequences of IL-31 monoclonal antibodies and methods of use. US20100008909 (2010).
114. Lee, H.-K. Alopecia healing apparatus using laser and LED. US7722655 (2010).
115. Al Mutairi N. 308nm excimer laser for the treatment of alopecia areata in children. Pediatr Dermatol 2009; 26(5): 547-50.
116. Vestey JP, Savin JA. Natural history of severe alopecia areata. Br J Dermatol 1987; 117(4): 531.
117. Sahn EE. Alopecia areata in childhood. Semin Dermatol 1995; 14(1): 9-14.
118. de Waard-van der Spek FB, Oranje AP, De Raeymaecker DM, Peereboom-Wynia JD. Juvenile versus maturity-onset al opecia areata-a comparative retrospective clinical study. Clin Exp Dermatol 1989; 14(6): 429-33.
119. Mitchell R, Sherker S, Cavanagh M, Eager D. Falls from playground equipment: will the new Australian playground safety standard make a difference and how will we tell? Health Promot J Austr 2007; 18(2): 98-104.
120. Tang L, Lui H, Sundberg JP, Bissonnette R, McLean DI, Shapiro J. Restoration of hair growth with topical diphencyprone in mouse and rat models of alopecia areata. J Am Acad Dermatol 2003; 49(6): 1013-9.
121. Tang L, Cao L, Bernardo O, Chen Y, Sundberg JP, Lui H, et al. Topical mechlorethamine restores autoimmune-arrested follicular activity in mice with an alopecia areata-like disease by targeting infiltrated lymphocytes. J Invest Dermatol 2003; 120(3): 400-6.
122. Tang L, Cao L, Sundberg JP, Lui H, Shapiro J. Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. Exp Dermatol 2004; 13(1): 5-10.
123. Shapiro J, Sundberg JP, Bissonnette R, McElwee KJ, McLean DI, Carroll JM, et al. Alopecia areata-like hair loss in C3H/HeJ mice and DEBR rats can be reversed using topical diphencyprone. J Invest Dermatol 1999; 4(3): 239.
124. Tang L, Sundberg JP, Lui H, Shapiro J. Old wine in new bottles: Reviving old therapies for alopecia areata using rodent models. J Invest Dermatol Symposium Proceedings 2003; 8(2): 212-6.
125. Verma DD, Verma S, McElwee KJ, Freyschmidt-Paul P, Hoffman R, Fahr A. Treatment of alopecia areata in the DEBR model using Cyclosporin A lipid vesicles. Eur J Dermatol 2004; 14(5): 332-8.
126. van den Biggelaar FJ, Smolders J, Jansen JF. Complementary and alternative medicine in alopecia areata. Am J Clin Dermatol 2010; 11(1): 11-20.